Literature DB >> 28114285

HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.

A Guo1, P Lu1, J Lee1, C Zhen1, G Chiosis2, Y L Wang1.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells in the hematopoietic system and lymphoid tissues. Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in the treatment of the disease, the underlying mechanisms leading to BCR over-activity in CLL are not fully understood. In this study, we found that HSP90, a highly conserved molecular chaperone, is overexpressed in CLL compared with resting B cells. HSP90 overexpression is accompanied by the overexpression of several BCR kinases including LYN, spleen tyrosine kinase, Bruton tyrosine kinase and AKT. Chemical and immune-precipitation demonstrated that these BCR constituents are present in a multi-client chaperone complex with HSP90. Inhibition of HSP90 with PU-H71 destabilized the BCR kinases and caused apoptosis of CLL cells through the mitochondrial apoptotic pathway. Further, PU-H71 induced apoptosis in the presence of stromal co-culture or cytoprotective survival signals. Finally, genetic knockdown of HSP90 and its client AKT, but not BTK, reduced CLL viability. Overall, our study suggests that the chaperone function of HSP90 contributes to the over-activity of the BCR signaling in CLL and inhibition of HSP90 has the potential to achieve a multi-targeting effect. Thus, HSP90 inhibition may be explored to prevent or overcome drug resistance to single targeting agents.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28114285      PMCID: PMC5645670          DOI: 10.1038/onc.2016.494

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses.

Authors:  S Kitada; J Andersen; S Akar; J M Zapata; S Takayama; S Krajewski; H G Wang; X Zhang; F Bullrich; C M Croce; K Rai; J Hines; J C Reed
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

3.  Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.

Authors:  C Yang; P Lu; F Y Lee; A Chadburn; J C Barrientos; J P Leonard; F Ye; D Zhang; D M Knowles; Y L Wang
Journal:  Leukemia       Date:  2008-07-03       Impact factor: 11.528

Review 4.  Chemical Tools to Investigate Mechanisms Associated with HSP90 and HSP70 in Disease.

Authors:  Liza Shrestha; Hardik J Patel; Gabriela Chiosis
Journal:  Cell Chem Biol       Date:  2016-01-21       Impact factor: 8.116

5.  Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.

Authors:  Zibo Song; Pin Lu; Richard R Furman; John P Leonard; Peter Martin; Lauren Tyrell; Francis Y Lee; Daniel M Knowles; Morton Coleman; Y Lynn Wang
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

6.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Authors:  Rebecca L Goldstein; Shao Ning Yang; Tony Taldone; Betty Chang; John Gerecitano; Kojo Elenitoba-Johnson; Rita Shaknovich; Wayne Tam; John P Leonard; Gabriela Chiosis; Leandro Cerchietti; Ari Melnick
Journal:  J Clin Invest       Date:  2015-11-03       Impact factor: 14.808

7.  Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia.

Authors:  Olga Grzybowska-Izydorczyk; Barbara Cebula; Tadeusz Robak; Piotr Smolewski
Journal:  Eur J Cancer       Date:  2010-01-04       Impact factor: 9.162

8.  The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.

Authors:  Elisabeth Walsby; Lawrence Pearce; Alan K Burnett; Chris Fegan; Chris Pepper
Journal:  Oncotarget       Date:  2012-05

9.  Mutations driving CLL and their evolution in progression and relapse.

Authors:  Dan A Landau; Eugen Tausch; Amaro N Taylor-Weiner; Chip Stewart; Johannes G Reiter; Jasmin Bahlo; Sandra Kluth; Ivana Bozic; Mike Lawrence; Sebastian Böttcher; Scott L Carter; Kristian Cibulskis; Daniel Mertens; Carrie L Sougnez; Mara Rosenberg; Julian M Hess; Jennifer Edelmann; Sabrina Kless; Michael Kneba; Matthias Ritgen; Anna Fink; Kirsten Fischer; Stacey Gabriel; Eric S Lander; Martin A Nowak; Hartmut Döhner; Michael Hallek; Donna Neuberg; Gad Getz; Stephan Stilgenbauer; Catherine J Wu
Journal:  Nature       Date:  2015-10-14       Impact factor: 49.962

10.  BCR and chemokine responses upon anti-IgM and anti-IgD stimulation in chronic lymphocytic leukaemia.

Authors:  Andrea Haerzschel; Julie Catusse; Evelyn Hutterer; Manuela Paunovic; Katja Zirlik; Hermann Eibel; Peter W Krenn; Tanja N Hartmann; Meike Burger
Journal:  Ann Hematol       Date:  2016-08-20       Impact factor: 3.673

View more
  14 in total

Review 1.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 2.  Adapting to stress - chaperome networks in cancer.

Authors:  Suhasini Joshi; Tai Wang; Thaís L S Araujo; Sahil Sharma; Jeffrey L Brodsky; Gabriela Chiosis
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

3.  First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.

Authors:  Mark P S Dunphy; Christina Pressl; Nagavarakishore Pillarsetty; Milan Grkovski; Shanu Modi; Komal Jhaveri; Larry Norton; Bradley J Beattie; Pat B Zanzonico; Danuta Zatorska; Tony Taldone; Stefan O Ochiana; Mohammad M Uddin; Eva M Burnazi; Serge K Lyashchenko; Clifford A Hudis; Jacqueline Bromberg; Heiko M Schöder; Josef J Fox; Hanwen Zhang; Gabriela Chiosis; Jason S Lewis; Steven M Larson
Journal:  Clin Cancer Res       Date:  2020-05-04       Impact factor: 12.531

4.  Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.

Authors:  Jimmy Lee; Liang Leo Zhang; Wenjun Wu; Hui Guo; Yan Li; Madina Sukhanova; Girish Venkataraman; Shengjian Huang; Hui Zhang; Mir Alikhan; Pin Lu; Ailin Guo; Natalie Galanina; Jorge Andrade; Michael L Wang; Y Lynn Wang
Journal:  Blood Adv       Date:  2018-08-28

5.  Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation.

Authors:  Takeshi Maehana; Toshiaki Tanaka; Kohei Hashimoto; Ko Kobayashi; Hiroshi Kitamura; Naoya Masumori
Journal:  Cell Stress Chaperones       Date:  2022-04-09       Impact factor: 3.827

Review 6.  Proteomic interrogation of HSP90 and insights for medical research.

Authors:  Lorenz Weidenauer; Tai Wang; Suhasini Joshi; Gabriela Chiosis; Manfredo R Quadroni
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

7.  HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.

Authors:  Şule Kale; Aylin F Korcum; Ertuğrul Dündar; Nuray Erin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-09-14       Impact factor: 3.000

8.  Effects of purine-scaffold inhibitors on HUVECs: Involvement of the purinergic pathway and interference with ATP. Implications for preventing the adverse effects of extracellular Grp94.

Authors:  Elisa Tramentozzi; Paola Finotti
Journal:  Biochem Biophys Rep       Date:  2019-07-03

Review 9.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

10.  HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells.

Authors:  Hasan Mahmud; Mariana Mendez; Bedabrata Mukhopadhyay; Jennifer Holter-Chakrabarty; Asish K Ghosh
Journal:  Oncotarget       Date:  2020-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.